Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit (Details Narrative)

v3.19.3.a.u2
Stockholders' Deficit (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended
Sep. 10, 2019
Jul. 19, 2019
Jun. 24, 2019
May 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Jan. 02, 2020
Aug. 31, 2019
Jun. 30, 2019
Dec. 09, 2014
Reverse stock split     one-for-five hundred (1:500)              
Common stock, par value     $ 0.001   $ 0.001       $ 0.001  
Common stock, shares authorized     100,000,000   100,000,000       100,000,000  
Preferred stock, shares authorized         1,500,005       1,500,005 500,000
Preferred stock, par value         $ 0.01       $ 0.01  
Common stock issued during period   20,000     1,246,859          
Conversion price             $ 0.165      
Conversion price, decrease         $ 0.067          
Conversion price, increase         $ 0.906          
Conversion of principal and interest, aggregate amount         $ 318,768          
Additional paid in capital         47,766,162   $ 410,750   $ 45,713,322  
Embedded derivative liability         $ 924,744          
Common stock reserved for future issuances         77,292,139          
Share issued price per share   $ 1.99                
Proceeds from issuance of common stock   $ 39,800     $ 405,773        
Consulting expenses         39,800          
Number of restricted shares issued       78,000            
Share Based Compensation         $ 150,208        
Warrants to purchase common stock 1,000,000                  
Warrant exercise price $ 2.00                  
Warrant expiration date Sep. 10, 2022                  
Fair value of warrants $ 984,810                  
Share-based Payment Arrangement, Option [Member]                    
Granted exercise price         $ 76.37          
Share Based Compensation       $ 41,437            
Grant options to purchase         59,644          
Exercise price       $ 4.65            
Risk free rate       2.42%            
Dividend yield       0.00%            
Fair value term       10 years            
Expected volatility       268.00%            
Option granted value       $ 248,620            
Common Stock [Member]                    
Amount recorded to equity         $ 343,179          
Embedded conversion option derivatives         46,600          
Fair market value of shares issued value         71,011          
Loss on extinguishment         24,411          
Gain on extinguishment         44,587          
Additional paid in capital         160,205          
First Warrant [Member]                    
Warrants to purchase common stock               450,000    
Warrant exercise price               $ 2.25    
Second Warrant [Member]                    
Warrants to purchase common stock               300,000    
Warrant exercise price               $ 3.33    
Third Warrant [Member]                    
Warrants to purchase common stock               225,000    
Warrant exercise price               $ 4.50    
Warrant [Member]                    
Share Based Compensation         $ 984,810          
Warrants outstanding and exercisable         1,975,059          
Warrants expiration term description         As of December 31, 2019, there were 1,975,059 warrants outstanding and exercisable with expiration dates commencing May 2020 and continuing through August 2024, with a weighted average exercise price per share of $2.69.          
Restricted Stock Units (RSUs) [Member]                    
Number of restricted shares issued       117,000            
Granted exercise price       $ 4.25            
Share based compensation arrangement by share based payment award options grant date fair value       $ 497,240            
Share Based Compensation         $ 108,771          
Unrecognized restricted stock units expense         357,392          
Restricted Stock [Member]                    
Unvested stock option recognized         $ 196,824          
Chief Executive Officer [Member]                    
Common stock issued during period       58,500            
Number of restricted shares issued       39,000            
Option Description       The total 58,500 options have a term of 10 years from the date of grant and exercise price ranging from $4.25 to $4.675 per share. 1/3rd of these options shall vest every successive one-year anniversary, provided, that on each such vesting date, the Chief Executive Officer and Chief Scientific Officer are employed by the Company and subject to the other provisions of the employment agreement. The 58,500 stock options were valued using a Black-Scholes model with the following assumptions: stock price at valuation date of $4.25 based on quoted trading price on date of grant, exercise price of $4.65, dividend yield of zero, years to maturity of 10.00, a risk free rate of 2.42%, and expected volatility 268% for a total value of $248,620.            
Chief Executive Officer [Member] | Share-based Payment Arrangement, Option [Member]                    
Grant options to purchase       39,000            
Chief Scientific Officer [Member] | Share-based Payment Arrangement, Option [Member]                    
Grant options to purchase       19,500            
Convertible Debt [Member]                    
Conversion price         $ 0.3575          
Embedded derivative liability         $ 343,179          
Fair market value of shares         $ 343,179          
Series A Preferred Stock [Member]                    
Preferred stock, shares authorized         500,000       500,000  
Preferred stock, par value         $ 0.01       $ 0.01  
Preferred stock, shares issued         500,000       500,000  
Preferred stock, shares outstanding         500,000       500,000